Although full results are not known, Celgene announced in its second-quarter earnings release Thursday that the study had been stopped ahead of schedule because the difference between patients getting Revlimid and those on a control group was already apparent.

FORBES: Inside Medicine

In the jet lag period immediately following the time difference, they had trouble learning simple tasks that a control group easily mastered.

FORBES: Why Holiday Travel Makes You Dumb

The study didn't find any difference in disease progression a year after treatment between those taking lithium and the control group, researchers said.

WSJ: ALS Study Falls Short, But Use of Social Media Holds Promise